UBI Pharma Valuation

Is 6562 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6562 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6562's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6562's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6562?

Key metric: As 6562 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6562. This is calculated by dividing 6562's market cap by their current revenue.
What is 6562's PS Ratio?
PS Ratio	2.6x
Sales	NT$648.63m
Market Cap	NT$1.68b

6562 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	33x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6562's PS Ratio compare to its peers?

The above table shows the PS ratio for 6562 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.9x
1780 Allied Biotech	2.1x	n/a	NT$1.6b
4186 Taiwan Advance Bio-Pharmaceutical	4.1x	n/a	NT$1.4b
4160 Genetics Generation Advancement	3.4x	n/a	NT$2.3b
6814 Lukas Biomedical	5.8x	n/a	NT$1.2b
6562 UBI Pharma	2.6x	n/a	NT$1.7b

Price-To-Sales vs Peers: 6562 is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (3.5x).

Price to Sales Ratio vs Industry

How does 6562's PS Ratio compare vs other companies in the TW Biotechs Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	20.9x	28.6%
6562 UBI Pharma	2.6x	n/a	US$51.89m
3176 Medigen Biotechnology	3.4x	n/a	US$147.42m
4169 TCM Biotech International	4.2x	n/a	US$108.31m

12 Companies		Estimated Growth	Market Cap
Industry Avg.	20.9x	49.5%
6562 UBI Pharma	2.6x	n/a	US$51.89m

No more companies

Price-To-Sales vs Industry: 6562 is good value based on its Price-To-Sales Ratio (2.6x) compared to the TW Biotechs industry average (24.6x).

Price to Sales Ratio vs Fair Ratio

What is 6562's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6562 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6562's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.5b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.70

7.9%

26.7%

Winston Medical Supply

NT$1.6b

Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.

6817

NT$88.30

-1.6%

-13.4%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%